Related Experiment Video
Updated: Jun 28, 2026
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
Published on: September 13, 2017
Role of full-length osteoprotegerin in tumor cell biology
G Zauli1, E Melloni, S Capitani
1Department of Morphology and Embryology, University of Ferrara, Via Fossato di Mortara 66, 44100 Ferrara, Italy. giorgio.zauli@unife.it
Abstract:
Osteoprotegerin (OPG) is a soluble tumor necrosis factor receptor family member, which potently inhibits RANKL-mediated osteoclastogenesis. Numerous constructs have been created for therapeutic purposes in which the heparin-binding and death homology domains of OPG were removed and the remaining peptide (amino acids 22-194) was fused to the Fc domain of human IgG1 (OPG-Fc). The administration of OPG-Fc efficiently counteracted bone loss in a variety of preclinical models of cancers. However, several in vitro studies have shown that native or recombinant full-length OPG not only neuralizes RANKL, but also the death-inducing ligand TRAIL, suggesting that OPG might potentially counteract the anti-tumor activity of TRAIL. Additional evidence suggests that full-length OPG possesses RANKL- and TRAIL-independent biological properties, mainly related to the promotion of endothelial cell survival and angiogenesis. Finally, breast tumor cells overexpressing OPG have shown increased bone metastatic potential in vivo. The relevance of these apparently conflicting findings in tumor cell biology is highlighted.
Insights
Osteoprotegerin (OPG) inhibits bone loss but full-length OPG may counteract anti-tumor activity. OPG-Fc constructs are effective against cancer-related bone loss, yet OPG’s complex roles in tumor biology require further investigation.
Area of Science:
- Oncology
- Bone Biology
- Molecular Biology
Background:
- Osteoprotegerin (OPG) is a key regulator of bone metabolism, inhibiting osteoclastogenesis via RANKL neutralization.
- Therapeutic constructs like OPG-Fc (amino acids 22-194 fused to human IgG1 Fc domain) have shown efficacy in preclinical models of cancer-induced bone loss.
- Full-length OPG interacts with TRAIL and possesses independent roles in endothelial cell survival and angiogenesis, presenting a complex biological profile.
Purpose of the Study:
- To investigate the multifaceted roles of Osteoprotegerin (OPG) in cancer, particularly concerning bone metastasis and anti-tumor activity.
- To evaluate the therapeutic potential and limitations of OPG-Fc constructs in preclinical cancer models.
- To reconcile conflicting findings regarding OPG's effects on tumor cell biology and angiogenesis.
Main Methods:
- Utilized preclinical models to assess the efficacy of OPG-Fc in counteracting cancer-related bone loss.
- Conducted in vitro studies to examine the interactions of full-length OPG with RANKL and TRAIL.
- Investigated OPG's independent effects on endothelial cell survival and angiogenesis.
Main Results:
- OPG-Fc administration effectively mitigated bone loss in various preclinical cancer models.
- Full-length OPG was found to neutralize both RANKL and TRAIL.
- Evidence suggests OPG promotes endothelial cell survival and angiogenesis, and OPG overexpression in breast tumor cells correlated with increased bone metastatic potential.
Conclusions:
- OPG-Fc is a promising therapeutic agent for managing cancer-associated bone loss.
- The dual action of full-length OPG on RANKL and TRAIL, along with its independent angiogenic properties, complicates its therapeutic application.
- Further research is needed to fully elucidate OPG's complex and sometimes contradictory roles in tumor progression and metastasis.
Related Concept Videos
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:38Mitogens and the Cell Cycle
02:17The Tumor Microenvironment
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...